CPP
AXDX icon

Crow Point Partners’s Accelerate Diagnostics AXDX Stock Holding History

Crow Point Partners’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-45
Closed -$10K – 131
2018
Q1 		$10K Buy
+45
New +$11.8K ﹤0.01% 251

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
ArrowMark Colorado Holdings
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Crow Point Partners's AXDX Position: Q2 2018 in Review

Crow Point Partners sold out of Accelerate Diagnostics (AXDX) in Q2 2018, closing a stake of 45 shares — an estimated $10K sold.

Crow Point Partners first reported a position in AXDX in Q1 2018 and held it in 1 quarter. The position peaked at $10K in Q1 2018. 116 funds tracked by Wall St. Rank hold AXDX as of Q2 2018.

  • Crow Point Partners reported no remaining Accelerate Diagnostics position as of Q2 2018 after selling out during the quarter.
  • Crow Point Partners sold 45 Accelerate Diagnostics shares in Q2 2018, an estimated $10K.
  • Crow Point Partners first reported a position in Accelerate Diagnostics in Q1 2018 and held it in 1 quarter.
  • Crow Point Partners's Accelerate Diagnostics position peaked at $10K in Q1 2018.
  • 116 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2018.

Based on Crow Point Partners's 13F filing for Q2 2018, filed 14 Aug 2018.